source
- cAMPfield Therapeutics raises $180 million to develop oral IBD drug prifemilastcAMPfield Therapeutics, a California biotech, announced a $180 million Series A financing to advance its oral anti‑inflammatory candidate for inflammatory bowel disease. The investigational drug,…
- Biogen to acquire RayThera in up to $1 billion deal for immunology pipelineBiogen announced it will acquire RayThera, a startup founded in 2023, in a deal valued at up to $1 billion. The acquisition gives Biogen access to RayThera’s immunology pipeline, which includes th…